The Soli‐D study demonstrated improved glycaemic control, body weight benefit, a greater proportion of participants at HbA1c target, lower total insulin dose and lower incidence and event rate of hypoglycaemia, albeit with an increased rate of gastrointestinal AEs.14 The gene discussed is INS; the disease is Hypoglycemia.